GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dar Al Dawa Development and Investment (AMM:DADI) » Definitions » 3-Year EPS without NRI Growth Rate

Dar Al Dawa Development and Investment (AMM:DADI) 3-Year EPS without NRI Growth Rate : 24.30% (As of Mar. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Dar Al Dawa Development and Investment 3-Year EPS without NRI Growth Rate?

Dar Al Dawa Development and Investment's EPS without NRI for the three months ended in Mar. 2024 was JOD0.01.

During the past 12 months, Dar Al Dawa Development and Investment's average EPS without NRI Growth Rate was 46.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 24.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Dar Al Dawa Development and Investment was 24.30% per year. The lowest was -49.10% per year. And the median was 0.30% per year.


Competitive Comparison of Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate falls into.



Dar Al Dawa Development and Investment 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Dar Al Dawa Development and Investment  (AMM:DADI) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Dar Al Dawa Development and Investment 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Dar Al Dawa Development and Investment's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Dar Al Dawa Development and Investment (AMM:DADI) Business Description

Traded in Other Exchanges
N/A
Address
Naour, P.O. Box 9364, Amman, JOR, 11191
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives of the company are to manufacture pharmaceutical, chemical, pharmaceutical, and related products and to import medicines. It offers products in the therapeutic areas of anti-infective, cardiovascular and diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.

Dar Al Dawa Development and Investment (AMM:DADI) Headlines

No Headlines